The START study is a randomized, double-blind, cancer cells thattrolled study, patients with documented unresectable stage III NSCLC rate a rate a response or stable disease after at least two cycles of platinum-based chemo-radiotherapy. The study was requested in accordance with scientific advice from the European Medicines Agency and the U.S. Food and Drug Administration on a Special Protocol Assessment agreed. Data from a randomized Phase IIb study encouraged the initiation of the Phase III program.
While the overall results of the study were not statistically significant, in the randomized patients with stage IIIB locoregional disease, Stimuvax showed a median survival of 30.6 months versus 13.3 months in the control group. An improvement of 17.3 months In the Phase IIb study, side effects were primarily limited to mild-to – moderate flu-like symptoms, GI disturbances and mild reactions at the injection site.. For more information on the START study or participating centers and of the of the study are also listedAbout StimuvaxStimuvax is an innovative cancer vaccine designed to induce an immune response to induce cancer cells, MUC1, a protein antigen MUC1 common cancers. MUC1 over expressed on many cancers such as lung cancer, breast and colorectal cancers.In their background information described in the researchers, such as movies and ads In more general terms alcohol in a positive way and which assumption here is that those young people, is promote drinking. So they decided for testing an experiment. – They drafted is a naturalistic setting described where Friendlies pairs of the young men a film the Home Cinema – style for 1 h, includes 2 could watch commerical pause. Whereas they did they had access to a refrigerator fill with alcoholic and soft beverages. The idea was of replicating an observable friendly version Home-based television.